Molecular Partners (MOLN) said late Wednesday that updated data from a phase 1/2a study of MP0533 showed three out of eight patients with relapsed or refractory acute myeloid leukemia responded after the first cycle of a steeper step-up dosing in group eight.
One patient in the group achieved a complete response, while the remaining two patients had a complete response with partial hematologic recovery, the company said.
The company said it is dosing patients in group nine and expects data from the amended dosing scheme in H2.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.